News
Co-organizing the grand event and sharing cutting-edge insights: Jinlangbo made its debut at the 2025 China Vitamin Industry Development High-Level Forum, delivering a keynote report.
Release time:
2025-12-08
Co-organize the grand event and share cutting-edge insights.
Jinlangbo made an appearance at the 2025 China Vitamin Industry Development High-Level Forum and delivered a keynote report.
01
Join us in celebrating this industry event, The Voice of the Frontier Draws Attention
From December 3 to 5, the 2025 China Vitamin Industry Development High-Level Forum, themed “New Forces Reshaping the Competitive Landscape in a New Cycle,” was grandly held in Huayuan Village, Dongyang City, Zhejiang Province—the nation’s first “small city within a village.” The forum brought together experts and leaders from industry, academia, research, and application, engaging in in-depth discussions on industry trends, research advances, and technological innovation. As a co-organizer of the event, Jinlangbo joined its industry peers in this momentous occasion, jointly exploring technological breakthroughs and future prospects for the vitamin industry.
As a co-organizer of this forum, Jinlangbo was deeply involved in the event’s preparation and exchanges, actively fulfilling its mission to advance the industry. At the highly anticipated thematic forum, the company’s Technical Director, Wang Zhongqiang, was invited to deliver a presentation titled “Quality and Process Evolution of 25-Hydroxyvitamin D3,” sharing the company’s latest research findings and industry insights in this field.
02
In-depth Analysis of Quality and Process Evolution
In the report, General Manager Wang provided an in-depth analysis from multiple perspectives—including key challenges in animal health, product‑value mechanisms, global quality standards, and manufacturing processes—drawing significant attention from the industry. The report systematically compared the purity, impurity, and residue limits for 25‑OHD3 as stipulated by major regulatory frameworks in China, the United States, and Europe, while emphasizing that Jingxin’s new product has undergone testing by a U.S.-based third‑party laboratory, with no detectable levels of the critical risk substance calcitriol (below 1 ppb), underscoring the company’s rigorous quality‑control measures. Additionally, the report highlighted Jingxin’s comprehensive, end‑to‑end value chain in the 25‑OHD3 space, covering the entire synthetic pathway—from cholesterol and intermediates to the final finished product.
03
The exchanges yielded fruitful results, strengthening industry ties.
During the forum, the company’s team engaged in extensive and in-depth exchanges with renowned experts and partners from both China and abroad. Through technical discussions and industry dialogues, the company not only showcased its expertise in the vitamin sector but also strengthened its ties within the industry, laying a solid foundation for future collaborations.
Through continuous process optimization and stringent quality control, Jinlangbo delivers a more efficient and stable 25‑OHD3 solution to the industry, helping to enhance animal health and farming productivity. Looking ahead, Jinlangbo will further deepen its innovation efforts, driving vitamin nutrition toward greater precision and sustainability.
More news
Address: No. 53 Yulin Road, Yulin Street, Xinchang County, Zhejiang Province
Tel: +86-575-86297308 +86-575-86297565
Fax: 0575-86297657
Email: jinlangbo@jingxinpharm.com